Eupraxia Pharmaceuticals Inc

EPRX05 Dec 2024
Healthcare
$3.28
-0.03 (-3.08%)
Lowest Today
$2.96
Highest Today
$3.28
Today’s Open
$3.28
Prev. Close
$3.25
52 Week High
$4.08
52 Week Low
$2.2
To Invest in Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc

Healthcare
EPRX05 Dec 2024
-0.03 (-3.08%)
1M
3M
6M
1Y
5Y
Low
$2.96
Day’s Range
High
$3.28
2.96
52 Week Low
$2.2
52-Week Range
52 Week High
$4.08
2.2
1 Day
-
1 Week
-6.16%
1 month return
+4.36%
3 month return
+35.08%
6 month return
+23.61%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-
Fundamentals
Market Cap
91.91 mln
PB Ratio
6.2
PE Ratio
0
Enterprise Value
71.85 mln
Total Assets
20.27 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Organisation
Eupraxia Pharmaceuticals Inc
Employees
29
Industry
Biotechnology
CEO
Dr. James A. Helliwell FRCPC, M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step